OnKure grants 22,350 stock options to director

OnKure Therapeutics, Inc. director Andrew John Phillips received a grant of stock options covering 22,350 shares of Class A common stock at an exercise price of $4.14 per share.

Accepted by SEC EDGAR 08/11/2026 - 04:39 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. director Andrew John Phillips received a grant of stock options covering 22,350 shares of Class A common stock at an exercise price of $4.14 per share. The options expire on August 6, 2036 and vest 100% on the earlier of June 4, 2027 or the day prior to the company’s next annual meeting of stockholders, contingent on his continued service. Following this award, he holds options on 22,350 shares.

Insider Trade Summary

Grant/Award: 22,350 shares

Grant/Award 1 txn

Insider Phillips Andrew John

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	22,350	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 22,350 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

Key Figures

Option shares granted: 22,350 shares Exercise price: $4.14 per share Expiration date: August 6, 2036 +2 more

5 metrics

Option shares granted 22,350 shares Stock Option (right to buy) award to director Andrew John Phillips

Exercise price $4.14 per share Conversion or exercise price of the stock option

Expiration date August 6, 2036 Expiration of the stock option award

Total options after grant 22,350 shares Total derivative securities beneficially owned following the transaction

Vesting date reference June 4, 2027 100% vesting on earlier of this date or day prior to next annual meeting

Key Terms

Stock Option (right to buy), exercise price, vest, annual meeting of stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 4.1400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"100% of the shares subject to the option will vest on the earlier"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of stockholders financial

"the date of the Issuer's next annual meeting of stockholders"

service provider financial

"subject to the Reporting Person continuing as a service provider"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did Andrew John Phillips receive from OKUR?

Andrew John Phillips received a stock option grant for 22,350 shares of OnKure Therapeutics Class A common stock, with an exercise price of $4.14 per share and expiration on August 6, 2036, reported as directly held.

When do Andrew John Phillips’ new OKUR stock options vest?

The options vest 100% on the earlier of June 4, 2027 or the day prior to OnKure Therapeutics’ next annual meeting of stockholders, conditioned on Phillips continuing as a service provider through the applicable vesting date.

What is the exercise price of Andrew John Phillips’ OKUR stock options?

The reported exercise price is $4.14 per share for the stock options covering 22,350 underlying shares of OnKure Therapeutics Class A common stock, as disclosed in the derivative transaction details.

How many OKUR option shares does Andrew John Phillips hold after this grant?

After the reported grant, Andrew John Phillips holds stock options on 22,350 shares of OnKure Therapeutics Class A common stock, all reflected as direct ownership following the transaction.

Is the reported OKUR transaction a market purchase or sale?

The filing reports a grant/award acquisition of stock options, coded as an "A" transaction, rather than an open-market purchase or sale. It is a compensation-related derivative award with no per-share purchase price paid at grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Phillips Andrew John

(Last) (First) (Middle)

C/O ONKURE THEREAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.14	08/07/2026		A		22,350		(1)	08/06/2036	Class A Common Stock	22,350	$0	22,350	D

Explanation of Responses:

1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

	/s/ Rogan Nunn, by power of attorney	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)